219 related articles for article (PubMed ID: 17984172)
1. Comparative analysis of genetic modifiers in Drosophila points to common and distinct mechanisms of pathogenesis among polyglutamine diseases.
Branco J; Al-Ramahi I; Ukani L; Pérez AM; Fernandez-Funez P; Rincón-Limas D; Botas J
Hum Mol Genet; 2008 Feb; 17(3):376-90. PubMed ID: 17984172
[TBL] [Abstract][Full Text] [Related]
2. Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1.
Chen HK; Fernandez-Funez P; Acevedo SF; Lam YC; Kaytor MD; Fernandez MH; Aitken A; Skoulakis EM; Orr HT; Botas J; Zoghbi HY
Cell; 2003 May; 113(4):457-68. PubMed ID: 12757707
[TBL] [Abstract][Full Text] [Related]
3. Polyglutamine disease toxicity is regulated by Nemo-like kinase in spinocerebellar ataxia type 1.
Ju H; Kokubu H; Todd TW; Kahle JJ; Kim S; Richman R; Chirala K; Orr HT; Zoghbi HY; Lim J
J Neurosci; 2013 May; 33(22):9328-36. PubMed ID: 23719801
[TBL] [Abstract][Full Text] [Related]
4. Toward cell specificity in SCA1.
Humbert S; Saudou F
Neuron; 2002 May; 34(5):669-70. PubMed ID: 12062012
[TBL] [Abstract][Full Text] [Related]
5. Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases.
Ghosh S; Feany MB
Hum Mol Genet; 2004 Sep; 13(18):2011-8. PubMed ID: 15254017
[TBL] [Abstract][Full Text] [Related]
6. Identification of genes that modify ataxin-1-induced neurodegeneration.
Fernandez-Funez P; Nino-Rosales ML; de Gouyon B; She WC; Luchak JM; Martinez P; Turiegano E; Benito J; Capovilla M; Skinner PJ; McCall A; Canal I; Orr HT; Zoghbi HY; Botas J
Nature; 2000 Nov; 408(6808):101-6. PubMed ID: 11081516
[TBL] [Abstract][Full Text] [Related]
7. CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation.
Al-Ramahi I; Lam YC; Chen HK; de Gouyon B; Zhang M; Pérez AM; Branco J; de Haro M; Patterson C; Zoghbi HY; Botas J
J Biol Chem; 2006 Sep; 281(36):26714-24. PubMed ID: 16831871
[TBL] [Abstract][Full Text] [Related]
8. dAtaxin-2 mediates expanded Ataxin-1-induced neurodegeneration in a Drosophila model of SCA1.
Al-Ramahi I; Pérez AM; Lim J; Zhang M; Sorensen R; de Haro M; Branco J; Pulst SM; Zoghbi HY; Botas J
PLoS Genet; 2007 Dec; 3(12):e234. PubMed ID: 18166084
[TBL] [Abstract][Full Text] [Related]
9. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice.
Zu T; Duvick LA; Kaytor MD; Berlinger MS; Zoghbi HY; Clark HB; Orr HT
J Neurosci; 2004 Oct; 24(40):8853-61. PubMed ID: 15470152
[TBL] [Abstract][Full Text] [Related]
10. A Drosophila homolog of the polyglutamine disease gene SCA2 is a dosage-sensitive regulator of actin filament formation.
Satterfield TF; Jackson SM; Pallanck LJ
Genetics; 2002 Dec; 162(4):1687-702. PubMed ID: 12524342
[TBL] [Abstract][Full Text] [Related]
11. Progress in pathogenesis studies of spinocerebellar ataxia type 1.
Cummings CJ; Orr HT; Zoghbi HY
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1079-81. PubMed ID: 10434309
[TBL] [Abstract][Full Text] [Related]
12. No association of the SCA1 (CAG)31 allele with Huntington's disease, myotonic dystrophy type 1 and spinocerebellar ataxia type 3.
Hellenbroich Y; Kaulich M; Opitz S; Schwinger E; Zühlke C
Psychiatr Genet; 2004 Jun; 14(2):61-3. PubMed ID: 15167689
[TBL] [Abstract][Full Text] [Related]
13. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice.
Emamian ES; Kaytor MD; Duvick LA; Zu T; Tousey SK; Zoghbi HY; Clark HB; Orr HT
Neuron; 2003 May; 38(3):375-87. PubMed ID: 12741986
[TBL] [Abstract][Full Text] [Related]
14. Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxias.
Bezprozvanny I
Neurochem Res; 2011 Jul; 36(7):1186-97. PubMed ID: 21210219
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1.
Zoghbi HY; Orr HT
J Biol Chem; 2009 Mar; 284(12):7425-9. PubMed ID: 18957430
[TBL] [Abstract][Full Text] [Related]
16. Spinocerebellar ataxia type 1--modeling the pathogenesis of a polyglutamine neurodegenerative disorder in transgenic mice.
Clark HB; Orr HT
J Neuropathol Exp Neurol; 2000 Apr; 59(4):265-70. PubMed ID: 10759181
[TBL] [Abstract][Full Text] [Related]
17. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1.
Lim J; Crespo-Barreto J; Jafar-Nejad P; Bowman AB; Richman R; Hill DE; Orr HT; Zoghbi HY
Nature; 2008 Apr; 452(7188):713-8. PubMed ID: 18337722
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetics of hereditary spinocerebellar ataxia: mutation analysis of spinocerebellar ataxia genes and CAG/CTG repeat expansion detection in 225 Italian families.
Brusco A; Gellera C; Cagnoli C; Saluto A; Castucci A; Michielotto C; Fetoni V; Mariotti C; Migone N; Di Donato S; Taroni F
Arch Neurol; 2004 May; 61(5):727-33. PubMed ID: 15148151
[TBL] [Abstract][Full Text] [Related]
19. The clinical diagnosis of autosomal dominant spinocerebellar ataxias.
Klockgether T
Cerebellum; 2008; 7(2):101-5. PubMed ID: 18418679
[TBL] [Abstract][Full Text] [Related]
20. Targeting several CAG expansion diseases by a single antisense oligonucleotide.
Evers MM; Pepers BA; van Deutekom JC; Mulders SA; den Dunnen JT; Aartsma-Rus A; van Ommen GJ; van Roon-Mom WM
PLoS One; 2011; 6(9):e24308. PubMed ID: 21909428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
